FAES FARMA has demonstrated its commitment in the field of allergic diseases by developing and marketing bilastine, the newest and most modern non-sedating H1 antihistamine.
The aim of the EAACI 2018 Symposium is to share the latest clinical evidence related to development of the new H1 antihistamine bilastine as part of our commitment as a company dedicated to the treatment of allergies in children, adults and the elderly.
